W
Won Young Tak
Researcher at Kyungpook National University Hospital
Publications - 228
Citations - 14248
Won Young Tak is an academic researcher from Kyungpook National University Hospital. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 42, co-authored 210 publications receiving 11800 citations. Previous affiliations of Won Young Tak include Yonsei University & Toronto General Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie Tung-Ping Poon,Kwang Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie Aude Le Berre,Gerold Meinhardt,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
Journal ArticleDOI
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson,Shukui Qin,Joong-Won Park,Ronnie T.P. Poon,Jean-Luc Raoul,Philip A. Philip,Chih-Hung Hsu,Tsung Hui Hu,Jeong Heo,Jianming Xu,Ligong Lu,Yee Chao,Eveline Boucher,Kwang Hyub Han,Seung Woon Paik,Jorge Robles-Aviña,Masatoshi Kudo,Lunan Yan,Abhasnee Sobhonslidsuk,Dmitry Komov,Thomas Decaens,Won Young Tak,Long Bin Jeng,David R. Liu,Rana Ezzeddine,Ian Walters,Ann-Lii Cheng +26 more
TL;DR: Brivanib had an acceptable safety profile, but was less well-tolerated than sorafenib, and both agents had similar antitumor activity, based on secondary efficacy end points.
Journal ArticleDOI
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet,Thomas Decaens,Jean-Luc Raoul,Eveline Boucher,Masatoshi Kudo,Charissa Chang,Yoon-Koo Kang,Eric Assenat,H. Y. Lim,Valérie Boige,Philippe Mathurin,Laetitia Fartoux,Deng-Yn Lin,Jordi Bruix,Ronnie T.P. Poon,Morris Sherman,J.-F. Blanc,Richard S. Finn,Won Young Tak,Yee Chao,Rana Ezzeddine,David R. Liu,Ian Walters,Joong-Won Park +23 more
TL;DR: In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS, and the observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
Journal ArticleDOI
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,Alfredo Guglielmi,Seung Woon Paik,Maria Reig,Do Young Kim,Gar Yang Chau,Angelo Luca,Luis Ruiz del Arbol,Marie Aude Leberre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.